Scientists from the University of Toronto (UofT) discovered that the heart drug sotagliflozin protects the kidneys and heart in patients with type 2 diabetes and chronic kidney disease (CKD), formerly known as chronic kidney failure. The work is available at: ASN Kidney Week 2023The world’s largest meeting of nephrologists.
The study authors used data from the phase 3 SCORED clinical trial, which included 10,584 patients with type 2 diabetes, chronic kidney disease, and cardiovascular disease. They received sotagliflozin or placebo. The follow-up period lasted an average of 16 months. Sotagliflozin reduced the risk of kidney damage or need for kidney transplant by 38%. It also reduced the risk of death from cardiovascular disease by 23%.
The new data is consistent with previous studies of similar drugs, SGLT inhibitors. Sotagliflozin is a drug approved in the United States under the name INPEFA to reduce cardiovascular risk in patients with heart failure or chronic kidney disease. It is especially beneficial for type 2 diabetes as it also helps lower blood sugar levels.
It was before to create A way to slow the deterioration of kidney function in diabetes.